39 results
8-K
EX-1.1
TRML
Tourmaline Bio Inc
26 Jan 24
Other Events
4:12pm
) No Material Actions or Proceedings. There is no action, suit, proceeding, inquiry or investigation brought by or before any legal or governmental entity … , threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
key risk factors such as low-density lipoprotein cholesterol; thus, the CANTOS study was the first significant investigation of a targeted anti … and potency, and of selected clinical investigation sites to assess compliance with GCPs; and
FDA review and approval, or licensure, of the BLA to permit
424B3
2a9kil8x506vz 8ii82s
15 Sep 23
Prospectus supplement
6:31am
S-4/A
6qxq6k
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
EX-3.3
ddg w2xujx
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
EX-10.1
0v9y4ivgk
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
EX-10.6
gkzp69l2 eowu
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
s4ztl1gd
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
EX-10.4
hxdi91iibqscj6hg010
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
elb0loxsre
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
fpt1msdezzm kwp
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am